PAR 7.32% 22.0¢ paradigm biopharmaceuticals limited..

A most comprehensive exploratory study..., page-17

  1. 48 Posts.
    lightbulb Created with Sketch. 9
    Good read Mozz, have taken some time away from HC/ markets but good to be back and reading again.

    I'm definitely reading much along the same lines as you described, it looks like there's a shift from the researchers and academics to view OA as a disease that we actually have a lot earlier than what we have previously thought, it's not longer just your elderly folk, there is evidence to suggest that a decent portion of young adults who partake in even just average amounts of contact sporting can develop these "Teeny tiny fractures" and can be a recurring event till a later flare up is noticed which then brings the OA diagnosis/treatment phase.

    The diagnostic pathway for OA is in my opinion 100% going to change in the next couple of years, it may even be the case that the earlier diagnosis of OA through improved diagnostic testing coupled with iPPS as THE frontline therapy is going to be your no brainer going forward. repairing the joint even prophylactically, the risks/benefits? more to be seen and definitely more for us to work on because the patients are fed up and so are the docs, they all deserve this drug.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
22.0¢
Change
0.015(7.32%)
Mkt cap ! $76.98M
Open High Low Value Volume
21.0¢ 22.5¢ 21.0¢ $242.2K 1.102M

Buyers (Bids)

No. Vol. Price($)
1 16020 22.0¢
 

Sellers (Offers)

Price($) Vol. No.
22.5¢ 310000 2
View Market Depth
Last trade - 16.10pm 04/11/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.